The Supreme Court of Israel recently held that Sanofi intentionally deceived and failed to provide material information to the Israeli Patent Office during the prosecution of a patent application in respect of Sanofi’s drug Plavix (Clopidogrel Bisulfate)1.
In a recent decision, the District Court of Tel Aviv confirmed that under Israeli law contracts for the payment of royalties subsequent to the term of the patent license may be voidable as against public policy.
Nondiscrimination Commitments in the Supply Chain
Recent years have seen an explosion in FRAND litigation, in which parties commit to license intellectual property under “fair, reasonable and non-discriminatory” (FRAND) terms, but they cannot agree on the meaning of that commitment.
The article was published in the Cloud Strategy magazine.